Trial Profile

A Phase 2, Multi-center, Open-label, Single Arm Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 15 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osugacestat (Primary)
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms TENACITY
Sponsors Ayala Pharmaceuticals

31 Mar 2022 Status changed from recruiting to active, no longer recruiting.
28 Mar 2022 According to an Ayala Pharmaceuticals media release, the company has elected to discontinue this study as part of its efforts to focus its resources on the more advanced programs and studies including the RINGSIDE study in desmoid tumors and the ACCURACY study for ACC.
04 Jan 2022 According to an Ayala Pharmaceuticals media release, preliminary data from this trial is expected in H2, 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com